Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
I'm PortAI, I can summarize articles.
Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. According to TipRanks, Meacham has an average return of 4.2% and a 55.14% success rate on recommended stocks. Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $488.86, which is a 19.88% upside from current levels. In a report released on October 9, Evercore ISI also maintained a Buy rating on the stock with a $475.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments